# US 2018/0022815 A1 · Bi-specific chimeric antigen receptor and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022815 A1
- Document ID: US20180022815A1
- Status: Published application
- Kind: A1
- Application number: 15/549,961
- Filed: 2016-02-09
- Published: 2018-01-25
- Earliest claimed: 2015-02-09
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Inc.
- Inventors: Lung-Ji CHANG
- Web page: https://patentgrep.com/patent/US20180022815A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/3061: {Blood cells}
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are bi-specific chimeric antigen receptors (CARs), such as those specific for CD138 and BCMA. Use of the CARs in immune cells (e.g., T cells), compositions, and methods are also contemplated.

## Claims

### Claim 1

A chimeric antigen receptor (CAR) specific for CD138 and BCMA.

### Claim 2 (depends on 1)

The CAR of claim 1, comprising a first antigen-binding domain for CD138 and a second antigen-binding domain specific for BCMA.

### Claim 3 (depends on 1, 2)

The CAR of claim 1 or claim 2, comprising a first single chain Fv (scFv) specific for CD138 and a second scFv specific for BCMA.

### Claim 4 (depends on 1, 2, 3)

The CAR of any one of claims 1 to 3, where the CAR further comprises a transmembrane domain.

### Claim 5 (depends on 4)

The CAR of claim 4, wherein the transmembrane domain is a CD28 transmembrane domain.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The CAR of any one of claims 1 to 5, wherein the CAR further comprises a co-stimulatory domain and/or a signaling domain.

### Claim 7 (depends on 6)

The CAR of claim 6, wherein the co-stimulatory domain is a 4-1BB co-stimulatory domain and/or the signaling domain is a CD27 signaling domain.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The CAR of any one of claims 1 to 7, wherein the CAR comprises a signal transduction domain.

### Claim 9 (depends on 8)

The CAR of claim 8, wherein the signal transduction domain is a CD3zeta signal transduction domain.

### Claim 10 (depends on 1, 2, 3)

The CAR of any one of claims 1 to 3, wherein the CAR further comprises one or more of a CD28 transmembrane domain, a 4-1BB co-stimulatory domain, a CD27 domain, and a CD3zeta signal transduction domain.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The CAR of any one of claims 1 to 10, further comprising a caspase 9 functional domain and/or a mutated FK506 binding protein (FKBP) motif.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The CAR of any one of claims 1 to 11, wherein the CAR is a homodimer.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The CAR of any one of claims 1 to 11, wherein the CAR is a heterodimer which comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises the scFv specific for CD138 and the second polypeptide comprises the scFv specific for BCMA.

### Claim 14 (depends on 13)

The CAR of claim 13, wherein each of the first and second polypeptide further comprise, independently, one or more of a CD28 transmembrane domain, a 4-1BB co-stimulatory domain, a CD27 signaling domain and a CD3zeta signal transduction domain.

### Claim 15 (depends on 14)

The CAR of claim 14, wherein each of the first and second polypeptide further comprise, independently, a caspase 9 functional domain and a mutated FK506 binding protein (FKBP) motif.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The CAR of any one of claims 1 to 15, wherein the CAR further comprises a CD28 extracellular domain.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

One or more nucleic acids comprising one or more sequences that encode the CAR of any one of claims 1 to 16.

### Claim 18 (depends on 17)

One or more lentiviral vectors comprising the one or more nucleic acids of claim 17.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A cell comprising a CAR of any one of claims 1 to 16 and/or the one or more nucleic acids of claim 17.

### Claim 20 (depends on 19)

The cell of claim 19, wherein the cell is a stem cell, NK cell, or T cell.

### Claim 21 (depends on 19)

The cell of claim 19, wherein the cell is a T cell.

### Claim 22 (depends on 19, 20, 21)

A composition comprising a plurality of the cell of any one of claims 19 to 21.

### Claim 23 (depends on 22)

The composition of claim 22, further comprising a pharmaceutically acceptable carrier.

### Claim 24 (depends on 17)

A method of generating a plurality of CAR modified cells, the method comprising:
introducing one or more lentiviral vectors comprising the one or more nucleic acids of claim 17 into a plurality of immune cells.

### Claim 25 (depends on 24)

The method of claim 24, wherein the immune cells are T cells.

### Claim 26 (depends on 19, 20, 21, 22, 23, 24, 25)

A method of treating a subject having cancer or at risk of having cancer, the method comprising:
administering the T cell of any one of claims 19 to 21, the composition of claim 22 or 23, or the plurality of cells produced by the method of claim 24 or 25, into a subject having cancer or at risk of having cancer.

### Claim 27 (depends on 26)

The method of claim 26, wherein the cancer is multiple myeloma.
